multiomics approach in metastatic clear renal cell carcnoma

Conditions: Metastatic Clear Cell Renal Carcinoma

Summary: the choice of the best strategy in treatment-naive metastatic clear-cell renal cell carcinoma (mccrcc) patients is becoming an issue, since no biomarkers are available to guide the treatment allocation strategy. the elucidation of predictive factors to develop tailored strategies of treatment is an urgent unmet clinical need. recently there has been a great deal of interest in non-invasive liquid biopsy methods for their ability to detect and characterize circulating cell-free dna (cfdna), extracellular vescicles associated rnas and circulating tumor cells and to allow longitudinal evaluation of tumor evolution. an additional field of intense research is also radiomics as a novel approach to develop predictive tools by correlating imaging features to tumor characteristics including histology, tumor grade, genetic patterns and molecular phenotypes, as well as clinical outcomes in patients with renal neoplasms. the use of computational approaches to integrate informations, obtained from genomic and transcriptomic analysis of neoplastic tissues and of cfdna) or microvescicle-associated rna in blood and from radiomics, can be exploited to define an optimal allocation strategy for patients with mccrcc undergoing first-line therapy and to identify novel targets in mccrcc. aims of the study are: to identify molecular subtypes, signatures or biomarkers in mccrcc associated with different clinical outcome by applying bioinformatic analysis; to extract descriptive features in mccrcc from radiological imaging data; to integrate omics-driven and clinic-pathological characteristics with radiomic features extracted from the tumor and tumor environment to inform on biological features relevant to therapy outcome. this multicentric prospective study will evaluate genomics and radiomics in treatment-naïve advanced ccrcc patients. 100 eligible patients will be identified after screening, candidate to receive first-line treatment as investigator choice per clinical practice. tissue and plasma samples and ct exams will be collected at different intervals to provide a comprehensive molecular profile and radiomic features extrapolation, respectively. artificial neural networks will be used to build a genomic-radiomic profile of patients to correlate to treatment response. this sample size will allow an exploratory analysis of the prognostic and predictive performance of the multiomic classifier, to be subsequently validated in a larger expansion cohort of patients.

impact in the last ten years the systemic treatment of metastatic renal cell carcinoma has been revolutioned with the introduction of at least ten active drugs. with the advent of novel immuno-based and tyrosine kinase inhibitors (tkis)-based combinations, the choice of the best strategy in treatment-naive metastatic clear-cell renal cell carcinoma (mccrcc) patients (pts) is becoming an issue, since no biomarkers are available to guide the treatment allocation strategy . in recent clinical trials, combination therapies including nivolumab plus ipilimumab, pembrolizumab plus axitinib, atezolizumab plus bevacizumab, avelumab plus axitinib, pembrolizumab plus lenvatinib and nivolumab plus cabozantinib exhibited significant benefits in terms of overall survival (os) and/or progression-free survival (pfs) for mrcc compared with sunitinib as a standard first-line treatment for mrcc . however, there is a clear need for clinical predictive biomarkers to guide optimal treatment decisions. through the above research the investigators are confident to provide proof of concept that combine the informations from genomics and radiomics using computational approaches such as machine learning, will provide an opportunity for a molecularly driven patient's stratification. rationale and feasibility biomarkers risk stratification models based on gene expression pattern (both messenger and long non-coding rna) in ccrcc have proven to have strong prognostic values. hence, there is an interest in the identification and development of treatment predictive biomarkers to enable precision oncology increasing drug response. multiple candidates for predictive biomarkers from plasma, tumor, and host tissues have been explored in patients with metastatic renal-cell carcinoma who are receiving systemic therapies, but, as yet, none have entered clinical practice and all require prospective validation in clinical trials. in the era of vegf inhibitors, the investigators counted on imdc (international metastatic rcc database consortium) model, considering karnofsky performance status \ upper limit of normal. checkmate 214 study showed that os and orr were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk pts. extended study follow-up of keynote-426 study demonstrated that the benefit in os and pfs is consistent in this class of patients's risk also with the io/tki combination therapy. the imdc score is confirmed to be prognostic in every combos study. pd-l1 has also been demonstrated to be a prognostic marker for poor prognosis in rcc, regardless of the type of treatment used. more recently pd-l1 expression has also been evaluated for its predictive role that is only partially confirmed in the checkmate-214 population that received io-io combo and considered a poor marker for targeted therapies. gene signatures from immotion 150 and 151 evidenced that two different signatures (angiogenesis versus immune signature) in rcc patients could predict the response to combo treatment. metabolomics have also been assessed as potential biomarkers for rcc giving new insights into the understanding of rcc clinical behavior and for the development of new therapeutic strategies. both tumor tissue and blood are interesting source for the study of potential biomarkers. plasma samples in particular have been analyzed to better understand the role of components of the proangiogenic and cellular proliferation pathways. another topic is the study of cytokines, circulating endothelial cells, and gene expression controlling mechanisms. moreover, germline genetic variations in important genes related to drug mechanism-of-action and metabolism have been under investigation as well as factors implicated in gene expression regulation by epigenetic mechanisms or by post-transcriptional regulation. radiomics computed tomography (ct) is widely available, routinely used in the care of patients with metastatic tumors treated with antiangiogenic therapy and yields quantitative digital data. many studies have used ct noninvasive imaging-based methods to assess the pathologic grade of renal tumor before surgery. various radiological features such as tumor size and pattern enhancement have been shown to correlate with tumor grade. however, it is difficult to predict the pathologic grade of renal tumor with only information obtained from traditional radiologic features. conversely, radiomics analysis involves the automatic extraction of data not recognizable to the human eye resulting in highly detailed imaging features regarding tumor structure, shape and image intensity. radiomics may provide a novel approach to develop predictive tools by correlating imaging features to tumor characteristics including histology, tumor grade, genetic patterns and molecular phenotypes, as well as clinical outcomes. extracting data from imaging the aim is to provide information beyond what can be achieved from human imaging interpretation alone. in clinical practice, the prediction of rcc aggressiveness through imaging findings remains a challenge. a retrospective study by shu et al. demonstrated that radiomics features could be used as biomarkers for the preoperative evaluation of the ccrcc fuhrman grades. in the post-treatment setting, radiomics may assist in predicting a response to systemic therapy, including to antiangiogenic treatment, which may not be adequately assessed with traditional size-based criteria. smith and colleagues used a custom post-processing software and algorithm to develop a novel system to quantify changes in the amount of vascularized tumor within specific attenuation thresholds, termed the vascular tumor burden. this semi automated biomarker, in addition to other tumor metrics, such as length, area, and mean attenuation, were used to predict response to antiangiogenic therapy with sunitinib. changes in the vascular tumor burden metric on initial post-therapy imaging after the initiation of sunitinib showed a better separation of progression free survival between non-responders and responders compared with other commonly used response criteria changes in tumor metrics, including length, area, mean attenuation, recist, choi, modified choi, mass, and 10% sum long diameter. extension of radiomic analysis through radiogenomics, radiometabolomics, and correlation with other epidemiologic, clinical, and tissue-based datasets have the potential to improve patient management in the era of personalized medicine. understanding what these technologies can offer will allow radiologists to play a larger role in the care of patients with rcc. ct dynamic contrast-enhanced is a capable tool to quantify tumor enhancement and its response to anti-angiogenetic therapies. han et al found a correlation between tumor renal enhancement at baseline and response and pfs after treatment with sunitinib or sorafenib. in contrast, other studies have demonstrated that although the perfusion parameters at baseline were higher in patients with longer survival times, they were not significantly predictive of outcome, except when a cut-off analysis was established. other ct-based methods for assessing tumor response to anti-angiogenic therapy and predicting clinical outcome are undergoing further evaluation. among them, radiomics ct features such as heterogeneity, entropy, and texture uniformity are additional parameters that show promise for assessing the anti-angiogenic response of metastatic renal cell carcinoma. the correlation of these imaging data with genomics (ie, radiogenomics), metabolomics (ie, radiometabolomics) and beyond, offers an opportunity to generate objective, quantitative biomarkers of tumor biology that may be used to predict patient's prognosis and likelihood of response to therapy, overcoming some of the challenges associated with disease heterogeneity. artificial intelligence artificial intelligence systems, in particular those based on machine learning and deep learning, are able to autonomously identify salient patterns and complex relationships among data by just looking at sample populations. their ability to process heterogeneous data, for both classification and prediction purposes, may provide a valid contribution to better stratify rcc patients. recently, some works have attempted to use machine and deep learning for the differentiation between benign and malignant small renal masses, based on textural analysis of ct scans, for the prediction of the fuhrman nuclear grade, and gene expression-based molecular signatures. overall, the stratification of rcc patients still remains a challenging task, especially when considering the molecular heterogeneity of kidney tumors. the ability to combine the information from genomics and radiomics using computational approaches based on machine learning, provides an opportunity to re-classify patients into subgroups that could better guide treatment strategies. both supervised and unsupervised techniques can be used to identify a biomarker signature-score as well as to predict response/resistance to therapies. preliminary data the investigators have preliminary biological data on blood samples of 32 mrcc patients obtained at treatment baseline. the majority of patients received as first line the combination of nivolumab and ipilimumab, 9 patients received sunitinib, 5 were administered with pazopanib, and 6 patients received cabozantinib. the molecular analysis was conducted using the ngs oncomine solid tumor panel (thermo fisher). twentyfive patients (78,1%) were carriers of a molecular alteration in one or more genes including: tp53, mtor, pik3ca, braf, egfr, ret, gnas, sf3b1, pdgfra. the reported allele frequency ranged between 3% and 12%. the preliminary analysis shows that patients with multiple mutations have a better response (pr+sd vs pd) from immunotherapy. experimental design this is a multicentric prospective translational study evaluating genomics and radiomics in treatment- naïve advanced ccrcc pts candidate to receive first-line systemic therapy. nine centers in italy, including: istituto nazionale dei tumori (int) of milan, european institute of oncology (ieo) of milan, istituto oncologico veneto (iov), policlinico san martino of genova, istituto nazionale dei tumori of napoli, university hospital of parma, humanitas research hospital of milan, oncological center of aviano and fondazione policlinico universitario agostino gemelli of rome will be involved in the accrual and the treatment of patients.

Eligibility criteria:
inclusion criteria: * signed written informed consent * male or female subjects aged ≥18 years old * histologically confirmed advanced/metastatic rcc with predominantly clear-cell subtype * previous nephrectomy is permitted * availability of tumor tissue sample for biomarker analysis * advanced (not amenable to curative surgery or radiation therapy) or metastatic (ajcc stage iv) rcc, candidate to receive first-line systemic treatment with monotherapy tki or io+tki or io+io * no prior systemic therapy for rcc with the following exception: prior adjuvant therapy for completely resectable rcc (concluded at least 6 months before study entry) * all imdc risk (good, intermediate, poor) * tc scan performed with and without contrast medium, at baseline (according to protocol guidelines as reported below in table 1) * at least one measurable lesion as defined by response evaluation criteria in solid tumors (recist) version 1.1 * eastern cooperative oncology group performance status 0 or 1 * capable of understanding and complying with the protocol requirements. exclusion criteria: * any prior systemic treatment for rcc in the advanced/metastatic settings * prior treatment with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody, or any other antibody or drug specifically targeting t-cell co-stimulation or checkpoint pathways * previous exposure to tyrosine kinase inhibitors in the advanced/metastatic settings * active seizure disorder or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis * diagnosis of any non-rcc malignancy occurring within 2 years prior to the date of the start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix or low-grade prostate cancer (≤pt2, n0; gleason 6) with no plans for treatment intervention * radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the start of treatment. subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.